
AVAH Stock Forecast & Price Target
AVAH Analyst Ratings
Bulls say
Aveanna Healthcare Hldgs is a strong performer in the home healthcare industry, with a diverse payor mix, strong financial track record, and a recent successful acquisition. Although facing potential risks such as legislative rate initiatives and labor difficulties, Aveanna's focus on preferred payor relationships and potential for growth through M&A make it a positive investment option, outlined in its upgraded rating and target price of $10.
Bears say
Aveanna Healthcare Hldgs is facing numerous challenges, including labor shortages, reimbursement pressures from government payors, and regulatory risks. The company's reliance on government reimbursement for its private duty services segment and home health and hospice segment exposes it to potential changes in reimbursement policies. Its medical solutions segment's preferred payor strategy and cross-sell opportunities may help mitigate these risks, but there is still uncertainty surrounding the company's growth potential. Additionally, there are risks related to potential M&A execution and integration, as well as potential prolonged pandemic-related headwinds. The company's recent deleveraging and positive free cash flow generation are encouraging, but these alone may not be enough to overcome the potential risks and challenges Aveanna faces.
This aggregate rating is based on analysts' research of Aveanna Healthcare Holdings and is not a guaranteed prediction by Public.com or investment advice.
AVAH Analyst Forecast & Price Prediction
Start investing in AVAH
Order type
Buy in
Order amount
Est. shares
0 shares